Prothena: Zacks Research Has Positive Outlook for Prothena Q2 Earnings

Prothena Co. plc ( NASDAQ:PRTA - Free Report ) - Equities researchers at Zacks Research boosted their Q2 2025 earnings estimates for shares of Prothena in a note issued to investors on Monday, January 27th. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings per share of ($1.36) for the quarter, up from their previous estimate of ($1.38). The consensus estimate for Prothena's current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Prothena's Q4 2025 earnings at $0.53 EPS, FY2025 earnings at ($3.49) EPS, Q1 2026 earnings at ($1.41) EPS, Q2 2026 earnings at ($1.13) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($3.28) EPS. Prothena ( NASDAQ:PRTA - Get Free Report ) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The business had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.22 million. During the same period in the prior year, the business posted $0.38 EPS. The company's revenue for the quarter was down 98.9% on a year-over-year basis. Read Our Latest Report on PRTA Prothena Price Performance Shares of Prothena stock opened at $14.23 on Thursday. The business has a 50 day moving average price of $14.43 and a 200 day moving average price of $17.74. The company has a market capitalization of $765.72 million, a P/E ratio of -5.74 and a beta of 0.10. Prothena has a 1 year low of $11.70 and a 1 year high of $31.03. Institutional Inflows and Outflows Institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its position in shares of Prothena by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock worth $158,000 after buying an additional 1,065 shares during the period. Chicago Partners Investment Group LLC acquired a new stake in shares of Prothena during the 4th quarter worth approximately $159,000. Intech Investment Management LLC acquired a new position in Prothena in the third quarter valued at approximately $210,000. XTX Topco Ltd bought a new position in Prothena in the third quarter valued at approximately $260,000. Finally, Orion Portfolio Solutions LLC grew its holdings in Prothena by 4.4% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock worth $293,000 after acquiring an additional 739 shares during the period. 97.08% of the stock is owned by institutional investors. Prothena Company Profile ( Get Free Report ) Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Featured Articles Five stocks we like better than Prothena What is the Hang Seng index? Nebius Group: Market Overreaction or Real AI Disruption? Insider Selling Explained: Can it Inform Your Investing Choices? The Best Way to Invest in Gold Is... Industrial Products Stocks Investing Why Nike Stock Could Be 2025's Top Comeback Play Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter .